Toward a Radically Simple Multi-Modal Nasal Spray for Preventing Respiratory Infections

In Vitro and mouse study showing benefit with PCANS (Pathogen Capture and Neutralizing Spray) in reducing viral load in respiratory infections. Authors demonstrate that PCANS effectively neutralizes both enveloped viruses (SARS-CoV-2, Influenza A) and non-enveloped viruses (adenovirus), as well as bacterial pathogens like E. coli and K. pneumoniae. In Vitro, PCANS prevents pathogen transport and reduces viral titer by over 99.99%. In a severe Influenza A mouse model, PCANS significantly reduced lung viral titer and ensured 100% survival. Additionally, PCANS provided broad-spectrum protection for at least 4 hours post-administration and exhibited a strong safety profile with no observed toxicity in repeated dosing. The spray shows potential as a daily-use prophylactic for respiratory infections, with demonstrated efficacy in pre-clinical models.